UK markets close in 8 hours 4 minutes

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.9700+0.1000 (+3.48%)
At close: 04:00PM EST
2.9000 -0.07 (-2.36%)
After hours: 07:43PM EST
Full screen
Trade prices are not sourced from all markets
Previous close2.8700
Bid0.0000 x 900
Ask0.0000 x 1800
Day's range2.8000 - 3.0200
52-week range2.7900 - 36.0000
Avg. volume969,554
Market cap34.794M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™

    BERWYN, Pa., January 18, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders, and anti-viral indications, reported positive results of four preclinical dermal safety studies for Epoladerm™ (diclofenac epolamine). Epoladerm is an investigational product candidate for the management of pain associated with osteoarthritis of the knee. From these recently concluded animal studies, r

  • Business Wire

    Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

    BERWYN, Pa., January 04, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax"), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.m. ET. Anthony Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Monday, J

  • Business Wire

    Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio

    BERWYN, Pa., December 28, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below.